Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis

The application of allogeneic hematopoietic cell transplantation (allo-HCT) in non-Hodgkin lymphoma (NHL) patients ≥65 years in the United States is limited by lack of Medicare coverage for this indication. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: Shah, Nirav N., Ahn, Kwang Woo, Litovich, Carlos, Fenske, Timothy S., Ahmed, Sairah, Battiwalla, Minoo, Bejanyan, Nelli, Dahi, Parastoo B., Bolaños-Meade, Javier, Chen, Andy I., Ciurea, Stefan O., Bachanova, Veronika, DeFilipp, Zachariah, Epperla, Narendranath, Farhadfar, Nosha, Herrera, Alex F., Haverkos, Bradley M., Holmberg, Leona, Hossain, Nasheed M., Kharfan-Dabaja, Mohamed A., Kenkre, Vaishalee P., Lazarus, Hillard M., Murthy, Hemant S., Nishihori, Taiga, Rezvani, Andrew R., D’Souza, Anita, Savani, Bipin N., Ulrickson, Matthew L., Waller, Edmund K., Sureda, Anna, Smith, Sonali M., Hamadani, Mehdi
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2018
Témata:
Transplantation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916010/
https://ncbi.nlm.nih.gov/pubmed/29685953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018018531
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky